



# The Coca-Cola Company

## A Different Time and P(l)ace

With the trajectory of the COVID-19 outbreak still unpredictable, KO did well, in our view, to shift the focus of yesterday's earnings call away from near-term hypotheticals to a more holistic discussion of its go-forward strategy. In particular, CEO James Quincey outlined a new set of 5 strategic priorities, three of which we highlight below:

With the next three years presenting a very different reality than anticipated just a few months ago, KO is accelerating efforts to optimize its portfolio...While KO has made progress on eliminating "zombie" SKUs over the past 3 years, we learned that >50% of KO's 400 master brands today are still single-country brands that in aggregate contribute a mere 2% to revenues. With the crisis highlighting the benefits of a more focused portfolio across the CPG industry, KO aims to be more deliberate in prioritizing fewer but bigger brands. The recent decision to discontinue Odwalla is case in point.

...whilst introducing greater discipline into innovation and marketing decisions to ensure the company can support its growth ambitions more efficiently... Again, scale is taking precedence with management highlighting both a shift to bigger, more targeted innovation bets in new growth avenues as well as long-term opportunities to improve marketing effectiveness and efficiency through scalable programs eg. a new "Together Tastes Better" campaign pairing Coke with meals that will kick off in the U.S. but be rolled out globally and tailored by market. While recent conversations on marketing have involved tactical changes to offset near-term volume deleverage, we believe this new perspective could drive more lasting P&L benefits.

...and strengthening RGM and in-market execution capabilities to foster stronger customer and consumer relationships as traffic recovers. KO aims to capitalize on changing channel dynamics (on-premise capacity, increased online penetration) with examples discussed including new partnerships in the on-premise channel to support a recovery, digital investments, partnerships with 3PP food aggregators and e-commerce platforms and accelerating owned B2B & DTC platforms.

### KO: Quarterly and Annual EPS (USD)

|        | 2019   |       | 2020  |       | 2021  |       | Change y/y |      |      |
|--------|--------|-------|-------|-------|-------|-------|------------|------|------|
| FY Dec | Actual | Old   | New   | Cons  | Old   | New   | Cons       | 2020 | 2021 |
| Q1     | 0.48A  | 0.51A | 0.51A | 0.51A | 0.50E | 0.47E | 0.52E      | 6%   | -8%  |
| Q2     | 0.63A  | 0.37E | 0.42A | 0.40E | 0.52E | 0.55E | 0.51E      | -33% | 31%  |
| Q3     | 0.56A  | 0.50E | 0.48E | 0.47E | 0.52E | 0.55E | 0.55E      | -14% | 15%  |
| Q4     | 0.44A  | 0.48E | 0.38E | 0.44E | 0.46E | 0.44E | 0.49E      | -14% | 16%  |
| Year   | 2.11A  | 1.86E | 1.79E | 1.84E | 2.00E | 2.01E | 2.06E      | -15% | 12%  |
| P/E    | 22.4   |       | 26.4  |       |       | 23.5  |            |      |      |

Source: Barclays Research.

Consensus numbers are from Bloomberg received on 21-Jul-2020; 12:50 GMT

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

PLEASE SEE ANALYST CERTIFICATION(S) AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 5.

### Equity Research

Consumer | U.S. CHPC & Beverages  
22 July 2020

|               |                                |
|---------------|--------------------------------|
| Stock Rating  | <b>OVERWEIGHT</b><br>Unchanged |
| Industry View | <b>NEUTRAL</b><br>Unchanged    |
| Price Target  | <b>USD 56.00</b><br>Unchanged  |

|                           |           |
|---------------------------|-----------|
| Price (21-Jul-2020)       | USD 47.20 |
| Potential Upside/Downside | +18.6%    |
| Tickers                   | KO        |

|                             |         |
|-----------------------------|---------|
| Market Cap (USD mn)         | 202719  |
| Shares Outstanding (mn)     | 4294.89 |
| Free Float (%)              | 89.68   |
| 52 Wk Avg Daily Volume (mn) | 15.6    |
| Dividend Yield (%)          | 3.47    |
| Return on Equity TTM (%)    | 51.53   |
| Current BVPS (USD)          | 4.07    |

Source: Bloomberg

|                   |                 |
|-------------------|-----------------|
| Price Performance | Exchange-NYSE   |
| 52 Week range     | USD 60.13-36.27 |



Source: IDC; Link to Barclays Live for interactive charting

### U.S. CHPC & Beverages

Lauren R. Lieberman

+1 212 526 3112

lauren.lieberman@barclays.com

BCI, US

Shirley C. Serrao, CFA

+1 212 526 7518

shirley.serrao@barclays.com

BCI, US

Kate Grafstein

+1 212 526 5755

kate.grafstein@barclays.com

BCI, US

Samira Somany

+1 212 526 4602

samira.somany@barclays.com

BCI, US

|                                   |                                 |
|-----------------------------------|---------------------------------|
| U.S. CHPC & Beverages             | Industry View: NEUTRAL          |
| <b>The Coca-Cola Company (KO)</b> | <b>Stock Rating: OVERWEIGHT</b> |

| Income statement (\$mn) | 2019A   | 2020E   | 2021E   | 2022E   | CAGR |
|-------------------------|---------|---------|---------|---------|------|
| Revenue                 | 37,280  | 32,451  | 35,633  | 37,774  | 0.4% |
| EBITDA (adj)            | 11,774  | 10,553  | 11,707  | 12,469  | 1.9% |
| EBIT (adj)              | 10,409  | 9,158   | 10,317  | 10,996  | 1.8% |
| Pre-tax income (adj)    | 11,310  | 9,619   | 10,822  | 11,629  | 0.9% |
| Net income (adj)        | 9,104   | 7,724   | 8,657   | 9,303   | 0.7% |
| EPS (adj) (\$)          | 2.11    | 1.79    | 2.01    | 2.16    | 0.7% |
| Diluted shares (mn)     | 4,314.0 | 4,318.3 | 4,316.0 | 4,316.0 | 0.0% |
| DPS (\$)                | 1.60    | 1.66    | 1.73    | 1.80    | 4.0% |

| Margin and return data   | Average |       |      |      |      |
|--------------------------|---------|-------|------|------|------|
| Gross margin (%)         | 60.7    | 59.4  | 61.0 | 61.4 | 60.6 |
| EBITDA (adj) margin (%)  | 31.6    | 32.5  | 32.9 | N/A  | 32.3 |
| EBIT (adj) margin (%)    | 27.9    | 28.2  | 29.0 | 29.1 | 28.6 |
| Pre-tax (adj) margin (%) | 30.3    | 29.6  | 30.4 | 30.8 | 30.3 |
| Net (adj) margin (%)     | 24.4    | 23.8  | 24.3 | 24.6 | 24.3 |
| ROIC (%)                 | 18.9    | 25.4  | 23.0 | 22.3 | 22.4 |
| ROA (%)                  | 9.7     | 9.3   | 9.5  | N/A  | 9.5  |
| ROE (%)                  | 43.2    | 141.1 | 67.8 | N/A  | 84.0 |

| Balance sheet and cash flow (\$mn) | CAGR   |        |        |        |        |
|------------------------------------|--------|--------|--------|--------|--------|
| Cash and equivalents               | 6,480  | 15,506 | 15,787 | 17,193 | 38.4%  |
| Total assets                       | 86,381 | 79,149 | 86,909 | 92,133 | 2.2%   |
| Short and long-term debt           | 42,763 | 52,234 | 52,234 | 52,234 | 6.9%   |
| Total liabilities                  | 65,283 | 73,674 | 74,131 | 74,147 | 4.3%   |
| Net debt/(funds)                   | 34,816 | 35,261 | 34,980 | N/A    | N/A    |
| Shareholders' equity               | 21,098 | 5,476  | 12,778 | 17,986 | -5.2%  |
| Change in working capital          | 366    | 423    | 548    | 123    | -30.4% |
| Cash flow from operations          | 10,471 | 7,900  | 9,705  | 9,987  | -1.6%  |
| Capital expenditure                | -2,054 | -974   | -1,710 | -1,813 | N/A    |
| Free cash flow                     | 8,417  | 6,927  | 7,994  | 8,174  | -1.0%  |

| Valuation and leverage metrics | Average |      |      |      |      |
|--------------------------------|---------|------|------|------|------|
| P/E (adj) (x)                  | 22.4    | 26.4 | 23.5 | 21.9 | 23.5 |
| EV/sales (x)                   | 5.9     | 6.8  | 6.2  | N/A  | 6.3  |
| EV/EBITDA (adj) (x)            | 18.6    | 20.8 | 18.8 | N/A  | 19.4 |
| EV/EBIT (adj) (x)              | 21.1    | 24.0 | 21.3 | N/A  | 22.1 |
| Equity FCF yield (%)           | 4.1     | 3.4  | 3.9  | N/A  | 3.8  |
| P/BV (x)                       | 9.7     | 37.2 | 15.9 | N/A  | 20.9 |
| Dividend yield (%)             | 3.4     | 3.5  | 3.7  | 3.8  | 3.6  |
| Total debt/capital (%)         | 67.0    | 90.5 | 80.3 | 74.4 | 78.1 |
| Net debt/EBITDA (adj) (x)      | 3.0     | 3.3  | 3.0  | N/A  | 3.1  |

| Selected operating metrics | Average |       |      |     |      |
|----------------------------|---------|-------|------|-----|------|
| Organic sales growth (%)   | 6.0     | -10.7 | 10.0 | N/A | 1.8  |
| Volume growth (%)          | 1.0     | -9.6  | 8.2  | N/A | -0.1 |
| Price growth (%)           | 5.0     | -2.8  | 2.9  | N/A | 1.7  |

|                     |           |
|---------------------|-----------|
| Price (21-Jul-2020) | USD 47.20 |
| Price Target        | USD 56.00 |

**Why Overweight?** We expect KO's comprehensive transformation to re-accelerate the top and bottom line. As the company demonstrates an ability to sustainably deliver its algorithm, we expect more valuation credit to be given.


|             |           |
|-------------|-----------|
| Upside case | USD 61.00 |
|-------------|-----------|

Our upside case assumes that KO trades at a +30% premium to Large-Cap Staples on upside 2021 EPS of \$2.10.

|               |           |
|---------------|-----------|
| Downside case | USD 46.00 |
|---------------|-----------|

Our downside case assumes that KO trades at a +15% premium to Large-Cap Staples on downside 2020 EPS of \$1.80.

#### Upside/Downside scenarios



Source: Company data, Bloomberg, Barclays Research  
Note: FY End Dec

Yesterday, KO reported 2Q20 Comparable EPS of \$0.42, which compares to Consensus \$0.40 and Barclays Research \$0.37. Below-the-line items were a 1c drag to earnings.

**What to do with the stock.** To be sure, there is still significant uncertainty ahead with regard to the course of the COVID-19 outbreak and extent/timeline of its impact on away-from-home consumption. That said, with headwinds likely to prove temporary over time and much of the market arguably already trading on “post-COVID” CY21 earnings power, we find it difficult to reconcile KO’s underperformance versus its peer set (down -15% YTD vs. XLP -2.5%).

## A Different Time and P(l)ace

As expected, global unit case volume for KO improved markedly over the course of 2Q (down mid-single digits in July MTD vs. -10% in June and -25% in April). That said, with the COVID-19 crisis yet to find its peak in certain regions and others still in the process of re-opening their economies and testing new thresholds for social interaction, the trajectory of the COVID-19 outbreak remains unpredictable. Against this backdrop, KO did well, in our view, to shift the focus of yesterday’s earnings call away from guess work around how the next six months could hypothetically play out and to a more holistic conversation around enhancements to its go-forward strategy intended to help restore the business to pre-COVID levels over time. Leveraging key learnings through the crisis, CEO James Quincey outlined a new set of 5 strategic priorities (replacing the ones introduced at CAGNY in February), three of which we highlight below:

**With the next three years presenting a very different reality than what would have been anticipated just a few months ago, KO is accelerating existing efforts to optimize its portfolio...**It’s been nearly 3 years since Mr. Quincey first discussed the concept of eliminating “zombies” with the Street – shutting down sub-scale, underperforming brands/SKUs soaking up critical resources that could be better allocated towards brands with building momentum. While there has been progress on the SKU front (eg. eliminating 700 SKUs in 2018 and 600 in 2019), with >50% of KO’s 400 current master brands highlighted as single-country brands that in aggregate contribute a mere 2% to annual revenues, it would appear that brand work has lagged at best. In this regard, it would seem KO isn’t going to let the current crisis go to waste and is redoubling efforts to streamline the portfolio. Recall, KO and other CPGs have tactically narrowed assortment through the peak of the lockdown periods in order to ease pressure on supply chains and minimize out of stocks for key SKUs. We’d think the background work enabling these moves similarly yielded the realization of just how fat the tail had become, with the recent decision to discontinue Odwalla being case in point.

**...whilst introducing greater discipline into innovation and marketing such that the company can support its growth ambitions more efficiently...**To improve the odds of success for “explorer” and “challenger” brands, KO is raising the bar on its innovation pipeline, shifting focus to bigger, more targeted bets in new growth avenues (eg. AHA sparkling which has achieved double-digit value share in the U.S. in its first 18 weeks on the market). Additionally, while the conversation on marketing in recent months has been more in the way of near-term tactical cuts or delays in spend to offset volume deleverage, Mr. Quincey discussed longer-term opportunities to improve marketing effectiveness and efficiency that we believe could drive more lasting benefits to the P&L. In particular, Mr. Quincey highlighted the importance of scalable initiatives eg. a new “Together Tastes Better” campaign pairing Coke with meals that will kick off in the U.S. but be rolled out globally and tailored by market.

**...and strengthening RGM and in-market execution capabilities to foster stronger customer and consumer relationships as traffic recovers.** To be sure, price-pack

architecture is the most widely discussed component of KO's Revenue Growth Management strategy, with yesterday's call highlighting refillable offerings in Latin America to address affordability and expanding package assortment in Japan to cater to bifurcating demand at the high and low-end of the pricing spectrum. That said, with the crisis breeding opportunity to collaborate more closely with struggling food-service/restaurant operators and accelerating e-commerce adoption in the industry, KO also discussed efforts to capitalize on changing channel dynamics. To this point, we heard several examples of new partnerships in the on-premise channel to support a recovery in its customer base (eg. a new "Open Like Never Before" campaign behind re-openings in Europe, a rapid response resource for food-service outlets in the U.S., touchless FreeStyle machines). Additionally, KO is also emphasizing investments in digital strategies to drive sales, efficiencies and data analytics across the business, including partnering with 3PP food aggregators and e-commerce platforms and accelerating proprietary B2B and DTC platforms. As we reflect on these developments, we are reminded of the Rubik's cube analogy first shared at CAGNY in February and, in particular, the role that data and analytics as well as healthy bottler relationships are playing in identifying and segmenting new growth opportunities.

**Changes to the model.** We are taking down our organic sales outlook for 2020 slightly to -11% (vs. -10% prior), driven by weaker concentrate shipments this quarter, offset by a more favorable outlook for 3Q given unit case volume exit rates and trends month-to-date in July. Including a ~300 bps headwind from currency and a +50bps contribution from M&A, we model net sales down ~15%. We look for gross margins to be down -120 bps reflecting volume deleverage in the P&L and currency pressure, offset by mix benefits from lower margin businesses growing more slowly than the balance of the portfolio eg. BIG, Costa. We look for SG&A to be up +70 bps including a -35% cut to currency-neutral marketing spend vs. our original estimates at the start of the year and a -15% cut to currency-neutral non-marketing opex leaving our operating margins up +30 bps for the year. Including higher interest expense from new debt issuances this quarter, we are taking down our estimates for full-year EPS by 7c to \$1.79.

For 3Q specifically, we model organic sales down -9% and net sales down -12% including a ~300 bps headwind from currency and a +70 bps tailwind from M&A. We assume a sequential improvement in trend versus 2Q across all segments with the biggest incremental change coming in EMEA and Global Ventures given mid-late 2Q re-openings in Europe (which would also benefit Costa) and the likelihood of some volatility in the U.S. given case resurgence in certain states in the country. We look for gross margins to be down -200 bps and SG&A to be down -220 bps including a -40% cut to currency-neutral marketing spend vs. our original estimates at the start of the year and a -20% cut to currency-neutral non-marketing opex leaving our operating margins up +20 bps.

## ANALYST(S) CERTIFICATION(S):

I, Lauren R. Lieberman, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

## IMPORTANT DISCLOSURES

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

### Availability of Disclosures:

Where any companies are the subject of this research report, for current important disclosures regarding those companies please refer to <https://publicresearch.barclays.com> or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

The analysts responsible for preparing this research report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities, the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst.

Analysts regularly conduct site visits to view the material operations of covered companies, but Barclays policy prohibits them from accepting payment or reimbursement by any covered company of their travel expenses for such visits.

Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <https://publicresearch.barclays.com/S/RD.htm>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://publicresearch.barclays.com/S/CM.htm>.

### Primary Stocks (Ticker, Date, Price)

**The Coca-Cola Company** (KO, 21-Jul-2020, USD 47.20), Overweight/Neutral, A/CD/CE/D/J/K/L/M/N

Unless otherwise indicated, prices are sourced from Bloomberg and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

### Disclosure Legend:

**A:** Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of the issuer in the previous 12 months.

**B:** An employee or non-executive director of Barclays PLC is a director of this issuer.

**CD:** Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by this issuer.

**CE:** Barclays Bank PLC and/or an affiliate is a market-maker in equity securities issued by this issuer.

**D:** Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.

**E:** Barclays Bank PLC and/or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer within the next 3 months.

**FA:** Barclays Bank PLC and/or an affiliate beneficially owns 1% or more of a class of equity securities of this issuer, as calculated in accordance with US regulations.

**FB:** Barclays Bank PLC and/or an affiliate beneficially owns a long position of more than 0.5% of a class of equity securities of this issuer, as calculated in accordance with EU regulations.

**FC:** Barclays Bank PLC and/or an affiliate beneficially owns a short position of more than 0.5% of a class of equity securities of this issuer, as calculated in accordance with EU regulations.

**FD:** Barclays Bank PLC and/or an affiliate beneficially owns 1% or more of a class of equity securities of this issuer, as calculated in accordance with South Korean regulations.

**GD:** One of the Research Analysts on the fundamental credit coverage team (and/or a member of his or her household) has a long position in the common equity securities of this issuer.

**GE:** One of the Research Analysts on the fundamental equity coverage team (and/or a member of his or her household) has a long position in the common equity securities of this issuer.

**H:** This issuer beneficially owns more than 5% of any class of common equity securities of Barclays PLC.

**I:** Barclays Bank PLC and/or an affiliate is party to an agreement with this issuer for the provision of financial services to Barclays Bank PLC and/or an affiliate.

**J:** Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities of this issuer and/or in any related derivatives.

## IMPORTANT DISCLOSURES CONTINUED

**K:** Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage services, if applicable) from this issuer within the past 12 months.

**L:** This issuer is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

**M:** This issuer is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

**N:** This issuer is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

**O:** Not in use.

**P:** A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for remuneration, other than normal course investment advisory or trade execution services.

**Q:** Barclays Bank PLC and/or an affiliate is a Corporate Broker to this issuer.

**R:** Barclays Capital Canada Inc. and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.

**S:** This issuer is a Corporate Broker to Barclays PLC.

**T:** Barclays Bank PLC and/or an affiliate is providing equity advisory services to this issuer.

**U:** The equity securities of this Canadian issuer include subordinate voting restricted shares.

**V:** The equity securities of this Canadian issuer include non-voting restricted shares.

### Risk Disclosure(s)

Master limited partnerships (MLPs) are pass-through entities structured as publicly listed partnerships. For tax purposes, distributions to MLP unit holders may be treated as a return of principal. Investors should consult their own tax advisors before investing in MLP units.

### Guide to the Barclays Fundamental Equity Research Rating System:

Our coverage analysts use a relative rating system in which they rate stocks as Overweight, Equal Weight or Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry (the "industry coverage universe").

In addition to the stock rating, we provide industry views which rate the outlook for the industry coverage universe as Positive, Neutral or Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

### Stock Rating

**Overweight** - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

**Equal Weight** - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

**Underweight** - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

**Rating Suspended** - The rating and target price have been suspended temporarily due to market events that made coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including where the Investment Bank of Barclays Bank PLC is acting in an advisory capacity in a merger or strategic transaction involving the company.

### Industry View

**Positive** - industry coverage universe fundamentals/valuations are improving.

**Neutral** - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.

**Negative** - industry coverage universe fundamentals/valuations are deteriorating.

Below is the list of companies that constitute the "industry coverage universe":

### U.S. CHPC & Beverages

|  |  |                                      |
|--|--|--------------------------------------|
| Brown-Forman (BFb)                       | Church & Dwight Co., Inc. (CHD)          | Clorox Company (CLX)                 |
| Coca-Cola European Partners PLC (CCE.AS) | Coca-Cola European Partners PLC (CCEP)   | Colgate-Palmolive (CL)               |
| Constellation Brands (STZ)               | Coty Inc. (COTY)                         | Edgewell Personal Care Company (EPC) |
| Energizer Holdings, Inc (ENR)            | International Flavors & Fragrances (IFF) | Keurig Dr Pepper (KDP)               |
| Kimberly-Clark Corp. (KMB)               | Molson Coors Beverage Company (TAP)      | Newell Brands Inc. (NWL)             |
| PepsiCo Inc. (PEP)                       | Procter & Gamble (PG)                    | Reynolds Consumer Products (REYN)    |
| The Coca-Cola Company (KO)               | The Estée Lauder Companies (EL)          |                                      |

### Distribution of Ratings:

## IMPORTANT DISCLOSURES CONTINUED

Barclays Equity Research has 1592 companies under coverage.

45% have been assigned an Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Buy rating; 50% of companies with this rating are investment banking clients of the Firm; 74% of the issuers with this rating have received financial services from the Firm.

38% have been assigned an Equal Weight rating which, for purposes of mandatory regulatory disclosures, is classified as a Hold rating; 44% of companies with this rating are investment banking clients of the Firm; 69% of the issuers with this rating have received financial services from the Firm.

15% have been assigned an Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Sell rating; 31% of companies with this rating are investment banking clients of the Firm; 58% of the issuers with this rating have received financial services from the Firm.

### Guide to the Barclays Research Price Target:

Each analyst has a single price target on the stocks that they cover. The price target represents that analyst's expectation of where the stock will trade in the next 12 months. Upside/downside scenarios, where provided, represent potential upside/potential downside to each analyst's price target over the same 12-month period.

### Top Picks:

Barclays Equity Research's "Top Picks" represent the single best alpha-generating investment idea within each industry (as defined by the relevant "industry coverage universe"), taken from among the Overweight-rated stocks within that industry. Barclays Equity Research publishes "Top Picks" reports every quarter and analysts may also publish intra-quarter changes to their Top Picks, as necessary. While analysts may highlight other Overweight-rated stocks in their published research in addition to their Top Pick, there can only be one "Top Pick" for each industry. To view the current list of Top Picks, go to the Top Picks page on Barclays Live (<https://live.barcap.com/go/keyword/TopPicks>).

To see a list of companies that comprise a particular industry coverage universe, please go to <https://publicresearch.barclays.com>.

### Types of investment recommendations produced by Barclays Equity Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.

### Disclosure of other investment recommendations produced by Barclays Equity Research:

Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to <https://live.barcap.com/go/research/Recommendations>.

### Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong Branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India Branch (Barclays Bank, India)

Barclays Bank PLC, Singapore Branch (Barclays Bank, Singapore)

Barclays Bank PLC, DIFC Branch (Barclays Bank, DIFC)



## IMPORTANT DISCLOSURES CONTINUED

## The Coca-Cola Company (KO / KO)

USD 47.20 (21-Jul-2020)

Stock Rating


OVERWEIGHT

Industry View

NEUTRAL

## Rating and Price Target Chart - USD (as of 21-Jul-2020)

Currency=USD



| Publication Date | Closing Price | Rating     | Adjusted Price Target |
|------------------|---------------|------------|-----------------------|
| 17-Jul-2020      | 46.82         |            | 56.00                 |
| 22-Apr-2020      | 45.68         |            | 50.00                 |
| 16-Apr-2020      | 47.10         |            | 56.00                 |
| 27-Mar-2020      | 42.81         |            | 48.00                 |
| 31-Jan-2020      | 58.40         |            | 63.00                 |
| 24-Jul-2019      | 53.78         |            | 58.00                 |
| 16-May-2019      | 49.58         |            | 54.00                 |
| 24-Apr-2019      | 47.98         |            | 53.00                 |
| 31-Oct-2018      | 47.88         |            | 51.00                 |
| 26-Jul-2018      | 46.24         |            | 50.00                 |
| 17-May-2018      | 42.30         | Overweight | 48.00                 |
| 15-Mar-2018      | 43.67         |            | 45.00                 |
| 27-Jul-2017      | 46.12         |            | 46.00                 |

On 21-Jul-2017, prior to any intra-day change that may have been published, the rating for this security was Equal Weight, and the adjusted price target was 45.00.

Source: Bloomberg, Barclays Research

Historical stock prices and price targets may have been adjusted for stock splits and dividends.

Source: IDC, Barclays Research

[Link to Barclays Live for interactive charting](#)

**A:** Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of The Coca-Cola Company in the previous 12 months.

**CD:** Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by The Coca-Cola Company.

**CE:** Barclays Bank PLC and/or an affiliate is a market-maker in equity securities issued by The Coca-Cola Company.

**D:** Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from The Coca-Cola Company in the past 12 months.

**J:** Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities by The Coca-Cola Company and/or in any related derivatives.

**K:** Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage services, if applicable) from The Coca-Cola Company within the past 12 months.

**L:** The Coca-Cola Company is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

**M:** The Coca-Cola Company is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

**N:** The Coca-Cola Company is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

**Valuation Methodology:** Our price target of \$56 is based on a 28x P/E reflecting a +25% premium to Large-Cap Staples peers on our CY21 EPS estimate of \$2.01.

**Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target:** 1) FX headwinds force downward revision of estimates, 2) Slowdown in CSD category growth, 3) More sugar taxes cloud the dialogue, 4) Deterioration in North American pricing environment would hurt results



## DISCLAIMER:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been prepared for institutional investors and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact [debtresearch@barclays.com](mailto:debtresearch@barclays.com). Clients that are subscribed to receive equity research reports, will not receive certain cross asset research reports co-authored by equity and FICC research analysts that are distributed as "institutional debt research reports" unless they have agreed to accept such reports. Eligible clients may get access to such cross asset reports by contacting [debtresearch@barclays.com](mailto:debtresearch@barclays.com). Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ("Third-Party Content"). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

**United Kingdom:** This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

**European Economic Area ("EEA"):** This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the *Autorité des marchés financiers* or the *Autorité de contrôle prudentiel*.

**Americas:** The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC ([www.iiroc.ca](http://www.iiroc.ca)), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A. This material is distributed in the Cayman Islands and in the Bahamas by Barclays Capital Inc., which it is not licensed or registered to conduct and does not conduct business in, from or within those jurisdictions and has

not filed this material with any regulatory body in those jurisdictions.

**Japan:** This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokuchō (kinsho) No. 143.

**Asia Pacific (excluding Japan):** Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker INZ000269539 (member of NSE and BSE); Depository Participant with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. BSIPL is also registered as a Mutual Fund Advisor having AMFI ARN No. 53308. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 22 67196363. Fax number: +91 22 67196399. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore Branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC or one of the Barclays group entities. None of Barclays Bank PLC, nor such Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001. This material is distributed in New Zealand by Barclays Bank PLC, but it has not been registered, filed or approved by any New Zealand regulatory authority or under or in accordance with the Financial Markets Conduct Act of 2013, and this material is not a disclosure document under New Zealand law.

**Middle East:** Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). This material does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase, any securities or investment products in the UAE (including the Dubai International Financial Centre) and accordingly should not be construed as such. Furthermore, this information is being made available on the basis that the recipient acknowledges and understands that the entities and securities to which it may relate have not been approved, licensed by or registered with the UAE Central Bank, the Dubai Financial Services Authority or any other relevant licensing authority or governmental agency in the UAE. The content of this report has not been approved by or filed with the UAE Central Bank or Dubai Financial Services Authority. Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

**Russia:** This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

**IRS Circular 230 Prepared Materials Disclaimer:** Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2020). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14

5HP. Additional information regarding this publication will be furnished upon request.

